Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML)

In brief

This is a randomized double blind placebo controlled study of azacitidine with or without birinapant in subjects with higher risk Myelodysplastic syndrome, secondary MDS or myelomonocytic leukemia (CMMoL) who are naïve, to azacitidine therapy. Pre-clinical and mechanistic studies support that azacitidine may modulate pathways that enable birinapant-mediated anti-tumor activity.

Key facts

Study ID
NCT02147873
Run by
TetraLogic Pharmaceuticals
People needed
118
Starts
2014-06-01
Expected to finish
2016-06-01
Last updated by the study team
2016-10-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.